Open AccessTherapeutic Efficacy of Cannabidiol (CBD): a Review of the Evidence From Clinical Trials and Human Laboratory Studies
Author(s) -
Dennis J. Sholler,
Lauren Schoene,
Tory R. Spindle
Publication year - 2020
Publication title -
current addiction reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 26
ISSN - 2196-2952
DOI - 10.1007/s40429-020-00326-8
Subject(s) - cannabidiol , medicine , clinical trial , cannabis , randomized controlled trial , adverse effect , anxiety , intensive care medicine , psychiatry , pharmacology , surgery
Global policy changes have increased access to products containing cannabidiol (CBD), a primary constituent of hemp and cannabis. The CBD product industry has experienced tremendous growth, in part, because CBD is widely touted as an effective therapeutic for myriad health conditions. However, only 1 CBD product (Epidiolex®) has been approved by the U.S. Food and Drug Administration (FDA) to date. There is substantial interest among consumers and the medical and scientific communities regarding the therapeutic potential of CBD, including for novel indications that are not recognized by the FDA. The purpose of this review was to synthesize available evidence from clinical research regarding the efficacy of CBD as a therapeutic.